Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07818525 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Impact of Baseline Hormonal Profiles (DHEAS, FSH, LH) on Treatment Response to Systemic Isotretinoin in Adult Female Patients With Acne Vulgaris

Name: The Impact of Baseline Hormonal Profiles (DHEAS, FSH, LH) on Treatment Response to Systemic Isotretinoin in Adult Female Patients With Acne Vulgaris — clinical trial record (NCT07818525)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhaseNot specified

SponsorBiruni University

Started2026-01-27

View on ClinicalTrials.gov ↗

Biruni University

80 trials monitored

See 1 trial at risk

Acne vulgaris is a common dermatological condition in adult women, often influenced by hormonal factors. Androgens such as dehydroepiandrosterone sulfate (DHEAS) can stimulate sebaceous gland activity, while gonadotropins (FSH and LH) reflect ovarian and hypothalamic-pituitary axis function. Although systemic isotretinoin is highly effective in severe or treatment-resistant acne, variability in treatment response has been observed among female patients. The role of baseline hormonal levels in predicting isotretinoin response remains unclear. Identifying hormonal predictors of treatment response may improve patient stratification and personalized management. Aim of the study is to evaluate whether baseline serum levels of DHEAS, FSH, and LH are associated with clinical response to systemic isotretinoin in women aged 18 years and older with acne vulgaris.

Trial Details

NCT Number	NCT07818525
Lead Sponsor	Biruni University
Conditions	Acne Vulgaris
Enrollment	64 participants
Start Date	2026-01-27
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-03 (estimated)
Updated on ClinicalTrials.gov	2026-09-14